Review
Open access
Sep 2026
ctDNA in the Management of Resectable & Advanced Colorectal Cancer: Current Status and Future Directions
Abstract Circulating tumor DNA (ctDNA) is an increasingly important biomarker for molecular residual disease (MRD) after curative-intent treatment of colorectal cancer (CRC), but its prognostic value must be distinguished from proven clinical utility. This structured narrative review synthesizes evidence from PubMed/ME...
H. Al-Shamsi, S. Rafii, S. Tirmazy et al.
· OncoTargets and Therapy · 0 citations